Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease

Abstract

Our study shows that DM2 is an independent risk factor for HCC and pre-exists to HCC occurrence. In DM2 patients with HCC, metformin therapy is associated with a reduced HCC risk and seems to have a protective effect on HCC development.